StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Bafna Pharmaceuticals (BAFNAPH)

Pharma · NSE · end-of-day 2026-10-21

₹461.15

Day change

-2.00%

1-year

+189.6%

From 52-week high

-2.0%

Weinstein stage

Stage 2

Minervini template

8/8

Bafna Pharmaceuticals closed at ₹461.15 on 2026-10-21, up 190% over the past year, 2% below its 52-week high. It meets 8 of 8 conditions of Minervini's trend template - a full pass; Weinstein's stage analysis reads stage 2 - advancing. Over the year its annualised volatility was about 51%, with a largest fall of 48% from a peak.

Price, RSI and MACD

6M1Y2Y3Y

Price · +238.0% over the period

RSI (14) · 86.0

MACD (12, 26, 9) · histogram +4.37

Price · +195.6% over the period

RSI (14) · 86.0

MACD (12, 26, 9) · histogram +4.37

Price · +447.1% over the period

RSI (14) · 86.0

MACD (12, 26, 9) · histogram +4.37

Price · +395.9% over the period

RSI (14) · 86.0

MACD (12, 26, 9) · histogram +4.37

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Beta
—	—	—	—	—	11.37	—	0.34

Investor methods

Method	Checks	Score	Verdict
Minervini	✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 99.16 ✓ Within 25% of the 52-week high · high 470.55 ✓ RS percentile 70 or more · RS 100 Minervini's trend template - the gate the scanner applies.	8/8	Pass
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 2 - advancing
CAN SLIM	— C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 470.55 ✓ S more volume on up days than down days (50 sessions) · 1.89x ✓ L RS percentile 80 or more · RS 100 — I institutional sponsorship rising (FII + DII) · not yet collected for this stock ✗ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 39% William O'Neil's growth-leader checklist.	3/4	Average
Darvas	✗ Box top confirmed (3 sessions below the new high) · top 470.55 — Box bottom confirmed (3 sessions holding) ✗ Close above the box top · close 461.15 ✓ Volume at least 1.5x its 50-day average · 2.7x Nicolas Darvas's box: a breakout above a confirmed box after a new high.	68/100	Forming
Turtle	✗ Close above the prior 55-session high · 470.55 ✗ Close above the prior 20-session high · 470.55 ✗ Close below the prior 20-session low · 323.50 Donchian channel breakout - the Turtle traders' entry.		No signal
Graham	Needs positive earnings and book value.		Not assessable

Each method's own rules, applied to this stock - shown as information, not a buy or sell signal. All were tested on available data.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
BAFNAPH this stock	+42.5	+93.6	+249.0	+227.1	+429.1	+247.8	—	11.37	—	—	—	—	—	—	—	—	—	0.34
BLISSGVS	-7.5	+36.6	+123.7	+292.3	+600.7	+478.8	47.5	5.44	11.5	16.8	—	0.00	28.1	6,492	1,005	142	12.9	1.10
VENUSREM	-5.0	-10.3	+43.9	+232.4	+494.9	+234.4	17.4	3.05	16.8	21.9	—	0.00	13.2	2,024	811	116	86.9	0.88
INDSWFTLAB	-9.7	+47.0	+140.6	+226.6	+281.4	+475.1	50.2	2.15	3.2	3.9	—	0.01	32.6	2,974	665	57	6.8	0.79
RUBICON	-16.4	-1.2	+55.1	+136.7	—	—	81.7	18.59	22.4	—	—	0.20	60.5	23,955	1,936	288	17.7	0.34
MOREPENLAB	-5.7	+117.0	+168.0	+134.8	+229.8	+127.0	45.1	5.07	7.9	10.1	—	0.16	39.5	6,324	1,951	140	2.6	1.47
SHILPAMED	-21.1	+37.8	+107.0	+129.0	+406.3	+187.0	55.3	6.38	9.8	11.4	—	0.25	—	16,524	1,682	297	15.3	0.88
LAURUSLABS	-0.2	+27.6	+83.6	+117.8	+401.9	+251.7	86.4	20.51	18.2	17.9	—	0.45	62.2	1.09L	8,839	1,252	23.3	0.74
ZIMLAB	-1.0	+13.5	+51.7	+91.7	+11.4	—	161.3	2.39	2.1	5.5	—	0.42	20.2	708	397	4	0.8	0.75
IOLCP	-14.1	+17.6	+85.1	+83.1	+91.2	+53.0	30.4	2.84	7.9	10.7	—	0.07	19.5	5,115	2,524	168	5.7	1.14
ACUTAAS	-8.0	-13.9	+30.1	+76.2	—	—	66.8	15.61	24.0	31.7	—	0.02	50.7	25,809	1,462	387	47.2	0.77

Returns are total over each period, not annualised - 5Y is the whole five-year change. A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Haleos Labs Medico Remedies Nectar Lifesciences Aarey Drugs & Pharmaceuticals Medicamen Biotech Wanbury Kronox Lab Sciences Zim Laboratories

← All NSE stocks · More Pharma stocks

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-21, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact